Skip to main content

Molzym Gets CE Mark for Sepsis PCR Test

NEW YORK (GenomeWeb News) – German firm Molzym has received the CE Mark for its PCR-based test for sepsis enabling the firm to market the test throughout the European Union.
 
Molzym’s SepsiTest detects more than 345 relevant sepsis pathogens and can provide results in less than four hours. The firm claims that it is the first PCR-based assay that can detect all of the relevant strains in one test.
 
“Broad-spectrum molecular sepsis diagnostics will for the first time enable early targeted treatments and SepsiTest will greatly support clinicians in their bedside decision-making,” Michael Lorenz, chief scientist at Bremen, Germany-based Molzym, said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.